Prospective monitoring of epstein-barr virus DNA in adult renal transplant recipients during the early posttransplant period: Role of mycophenolate mofetil

Transplantation

Volumn 87, Issue 6, 2009, Pages 852-856

  Holmes, Michael V ^a   Caplin, Ben ^a   Atkinson, Claire ^a   Smith, Colette ^a   Harber, Mark ^a   Sweny, Paul ^a   Haque, Tanzina ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Adult renal transplant recipients; Epstein Barr virus; Monitoring; Mycophenolate mofetil

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VIRUS DNA; DRUG DERIVATIVE; MYCOPHENOLIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KAPLAN MEIER METHOD; KIDNEY ALLOGRAFT REJECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; VIREMIA; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD; DRUG EFFECT; GENETICS; IMMUNOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS;

ADOLESCENT; ADULT; AGED; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; VIREMIA; YOUNG ADULT;

EID: 65549088504     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318199f983     Document Type: Article

References (23)

1. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein- Barr virus-associated diseases. Annu Rev Microbiol 2000; 54: 19.
2. Burns DM, Crawford DH. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Rev 2004; 18: 193.
3. Nalesnik MA. Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD). Springer Semin Immunopathol 1998; 20: 325.
4. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222.
5. Wagner HJ, Cheng YC, Huls MH, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979.
6. Savoie A, Perpete C, Carpentier L, et al. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83: 2715.
7. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123.
8. Hopwood PA, Brooks L, Parratt R, et al. Persistent Epstein-Barr virus infection: Unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients. Transplantation 2002; 74: 194.
9. Jabs WJ, Hennig H, Kittel M, et al. Normalized quantification by realtime PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. J Clin Microbiol 2001; 39: 564.
10. Loginov R, Aalto S, Piiparinen H, et al. Monitoring of EBV-DNAemia by quantitative real-time PCR after adult liver transplantation. J Clin Virol 2006; 37: 104.
11. Scheenstra R, Verschuuren EA, de HA, et al. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. Transpl Infect Dis 2004; 6: 15.
12. Bakker NA, Verschuuren EA, Erasmus ME, et al. Epstein-Barr virus- DNA load monitoring late after lung transplantation: A surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Transplantation 2007; 83: 433.
13. Merlino C, Cavallo R, Bergallo M, et al. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients. New Microbiol 2003; 26: 141.
14. Benden C, Aurora P, Burch M, et al. Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by realtime polymerase chain reaction. J Heart Lung Transplant 2005; 24: 2103.
15. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995; 17: 681.
16. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85.
17. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005; 56: 23.
18. Vegso G, Sebestyen A, Paku S, et al. Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas. Leuk Res 2007; 31: 1003.
19. Alfieri C, Allison AC, Kieff E. Effect of mycophenolic acid on Epstein- Barr virus infection of human B lymphocytes. Antimicrob Agents Chemother 1994; 38: 126.
20. Haque T, Thomas JA, Parratt R, et al. A prospective study in heart and lung transplant recipients correlating persistent Epstein-Barr virus infection with clinical events. Transplantation 1997; 64: 1028.
21. Morris PJ, Johnson RJ, Fuggle SV, et al. Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK. HLA Task Force of the Kidney Advisory Group of the United Kingdom Transplant Support Service Authority (UKTSSA). Lancet 1999; 354: 1147.
22. Rodrigo E, Ruiz JC, Pinera C, et al. Creatinine reduction ratio on posttransplant day two as criterion in defining delayed graft function. Am J Transplant 2004; 4: 1163.
23. Govani MV, Kwon O, Batiuk TD, et al. Creatinine reduction ratio and 24-hour creatinine excretion on posttransplant day two: Simple and objective tools to define graft function. J Am Soc Nephrol 2002; 13: 1645.